4.4 Article

Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy

Journal

CURRENT CANCER DRUG TARGETS
Volume 14, Issue 8, Pages 727-736

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009614666141020105502

Keywords

Breast cancer; endometrial cancer; metformin; nanotechnology; prostate cancer; ovarian cancer; pancreatic cancer; pathways

Categories

Funding

  1. Department of Science and Technology (DST), India
  2. SERB Division [SR/FT/LS147/2009]
  3. Council of Scientific and Industrial Research (CSIR), India [09/963 (0030)/2K 13-EMK-I]
  4. PG program in Nanotechnology under the DST Nano Mission

Ask authors/readers for more resources

Metformin, a biguanide, is a commonly administered drug for the management of type 2 diabetes mellitus. The drug received tremendous recognition, when retrospective studies proved metformin-associated reduction in cancer risk. Metformin has potential anticancer effects and an ability to suppress tumor growth both in vitro and in vivo. Activation of LKB1/AMPK pathway and cancer stem cell destruction along with cell cycle arrest and apoptosis induction are the proposed mechanisms of anticancer potential of metformin. Nanotechnology approaches have also been adopted for metformin delivery to cancer cells. This review directs on the application of metformin for the therapy of various cancers and also the different pathways responsible for the metformin derived anticancer effect. It also focuses on the pharmacological applications of metformin and the nanotechnology approaches for metformin delivery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available